US Patent 10040853 Methods and compositions involving NKG2D inhibitors and cancer
Patent 10040853 was granted and assigned to Fred Hutchinson Cancer Research Center on August, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+190 characters)
Article
Patent abstract
Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer.
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
100408530
Date of Patent
August 7, 2018
0Patent Application Number
143435430
Date Filed
September 7, 2012
0Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
100408530
Date of Patent
August 7, 2018
0Patent Application Number
143435430
Date Filed
September 7, 2012
0Patent Primary Examiner
Edits on 21 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 10040853 Methods and compositions involving NKG2D inhibitors and cancer
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
10040853
Date of patent
August 7, 2018
Patent application number
14343543
Date Filed
September 7, 2012
Patent primary examiner
Find more entities like US Patent 10040853 Methods and compositions involving NKG2D inhibitors and cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
